Semigran Marc 4
4 · Edgewise Therapeutics, Inc. · Filed Dec 27, 2024
Insider Transaction Report
Form 4
Semigran Marc
Chief Development Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-12-24−29,709→ 270,291 totalExercise: $8.94Exp: 2032-12-30→ Common Stock (29,709 underlying) - Exercise/Conversion
Common Stock
2024-12-24$8.94/sh+29,709$265,598→ 36,425 total - Sale
Common Stock
2024-12-24$29.66/sh−27,980$829,906→ 8,445 total - Sale
Common Stock
2024-12-24$30.08/sh−1,729$52,009→ 6,716 total
Footnotes (5)
- [F1]Includes 2,187 shares purchased on November 15, 2023, 2,254 shares purchased on May 15, 2024 and 2,275 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2024.
- [F3]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.03 to $30.02, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.03 to $30.13, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]1/4th of the shares subject to the option became vested and exercisable on December 19, 2023 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.